ECM
PDLI

ExodusPoint Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

ExodusPoint Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,158
Closed -$126K – 2588
2020
Q3 		$126K Buy
40,158
+27,724
+223% +$88.6K ﹤0.01% 1562
2020
Q2 		$36K Buy
+12,434
New +$39.3K ﹤0.01% 1694
2019
Q4 		– Sell
-103,011
Closed -$223K – 2070
2019
Q3 		$223K Buy
+103,011
New +$275K 0.01% 1066

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

ExodusPoint Capital Management's PDLI Position: Q4 2020 in Review

ExodusPoint Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 40,158 shares — an estimated $126K sold.

ExodusPoint Capital Management first reported a position in PDLI in Q3 2019 and held it in 3 quarters. The position peaked at $223K in Q3 2019. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • ExodusPoint Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • ExodusPoint Capital Management sold 40,158 PDL BioPharma, Inc. shares in Q4 2020, an estimated $126K.
  • ExodusPoint Capital Management first reported a position in PDL BioPharma, Inc. in Q3 2019 and held it in 3 quarters.
  • ExodusPoint Capital Management's PDL BioPharma, Inc. position peaked at $223K in Q3 2019.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.